Two Lymphoma Foundations Merge to Form the Lymphoma Research Foundation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 4
Volume 11
Issue 4

LOS ANGELES-The Lymphoma Research Foundation of America (LRFA) and the New York-based Cure For Lymphoma Foundation (CFL) have merged to become the Lymphoma Research Foundation (LRF), the nation’s only organization dedicated solely to funding lymphoma research and providing information, education, and support to all those touched by the disease.

LOS ANGELES—The Lymphoma Research Foundation of America (LRFA) and the New York-based Cure For Lymphoma Foundation (CFL) have merged to become the Lymphoma Research Foundation (LRF), the nation’s only organization dedicated solely to funding lymphoma research and providing information, education, and support to all those touched by the disease.

By reducing duplicative administrative and program costs, the new foundation expects to be able to enhance its services to patients, caregivers, and health care professionals.

LRFA and CFL have a collective 17 years of experience and have funded more than $7 million in lymphoma research. The new LRF will continue to fund basic, translational, and clinical research projects at the fellow and junior faculty levels.

The new foundation has offices in Los Angeles, focusing on patient services and educational and support programs, and New York, focusing on research grants, public policy and advocacy, finance and development, and professional education. More information is available online at www.lymphoma.org.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content